US Pharma MarketingTeva reports a single-shot success in celiac disease, heating the IL-15 market
Teva Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
A single injection of an experimental antibody significantly reduced intestinal damage among people with celiac disease who then ate gluten daily, Teva Pharmaceuticals said Wednesday.
The Israeli drugmaking giant reported topline ...
Source: Endpoints News